NCT05213195

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

Detailed description

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation.

Conditions

• Refractory Metastatic Colorectal Cancer

Interventions

Type	Name	Description
DRUG	NKG2D CAR-NK	NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.

Timeline

• Start date: 2021-12-10
• Primary completion: 2024-12-31
• Completion: 2025-06-30
• First posted: 2022-01-28
• Last updated: 2024-02-12

Locations

1 site across 1 country: China